For several decades mankind has looked to automate tedious and error-prone manual steps carried out in the laboratory, with a goal to improve scientific reproducibility and throughput. We recently spoke to Charles Fracchia, CEO and Co-Founder of BioBright, to learn how automation can be adopted to help researchers analyze their data.READ MORE
The European Proteomics Infrastructure Consortium providing access (EPIC-XS), funded as part of the Horizon 2020 Work programme, held its kick-off meeting in Amsterdam on April 25-26 2019. In this article, we discuss the objectives and highlights of the meeting.READ MORE
Francis S. Collins, M.D., Ph.D. Director of the National Institutes of Health, has recently directly addressed the issue of underrepresented groups in science: "Too often, women and members of other groups underrepresented in science are conspicuously missing in the marquee speaking slots at scientific meetings and other high-level conferences.”READ MORE
At Argonne National Laboratory, the Aurora supercomputer will lead the charge as the US's first system exceeding an exaflop, or a billion-billion calculations per second. In this article, we explore how Aurora could enable revolutionary advances in heterogeneous catalysis chemistry research, with implications for fossil fuel processing and small molecule conversion.READ MORE
This article dwells upon the challenges presented by prevailing data visualization solutions for drug discovery and covers how enablers such as AI and VR have transformed the drug discovery data visualization market. It touches upon examples of existing solutions, new players and upcoming industry partnerships.READ MORE
The final instalment of The Evolution of Proteomics series features an interview with Professor John Yates from the Department of Molecular Medicine at Scripps Research. The Yates laboratory is focused on developing strategies and tools in proteomics to answer basic biological questions.
AI is rapidly being adopted in the pharmaceutical industry. Nonetheless, much pharmaceutical development data is limited, resulting in restricted amounts of usable data. Sparse data AI – the application of AI to restricted amounts of data – is opening up novel avenues for enhanced drug development. In this article, Nanoform’s Jukka Corander looks at how sparse data can help pharma industry AI gain greater transparency and lead to more life-changing medicines reaching the market.
Structural biology has recently observed the marrying of two remarkably complimentary techniques for the study of protein structure and interaction: cross-linking mass spectrometry (XL-MS) and the Nobel prize winning cryogenic electron microscopy (cryo-EM).READ MORE
Richard Scheltema is an assistant professor at Utrecht University where he heads up the Scheltema laboratory within the wider context of the group of Albert Heck. The research group focuses on mass spectrometry (MS) based structural proteomics, for which they develop advanced liquid chromatography-mass spectrometry (LC-MS/MS) platforms and analysis software.READ MORE
In the wake of the "Me Too" (or #MeToo) movement, a spotlight has been cast on an additional obstacle that deters many individuals, particularly women, from working in STEM – the astonishingly high incidence of sexual harassment. In this article, we look at the extent of the issue and speak with some of the women that are working tirelessly to combat sexual harassment in STEM through a variety of organizations.READ MORE